1. Description of FDG and Prostate-Specific Membrane Antigen PET/CT Findings in Korean Patients With Advanced Metastatic Castration-Resistant Prostate Cancer.
- Author
-
Na SJ, Ha S, Kim IH, Lee JY, and O JH
- Subjects
- Humans, Male, Aged, Middle Aged, Republic of Korea, Aged, 80 and over, Retrospective Studies, Antigens, Surface metabolism, Glutamate Carboxypeptidase II metabolism, Positron Emission Tomography Computed Tomography methods, Prostatic Neoplasms, Castration-Resistant diagnostic imaging, Prostatic Neoplasms, Castration-Resistant pathology, Fluorodeoxyglucose F18, Radiopharmaceuticals
- Abstract
Objective: We aimed to describe the [
18 F]fluorodeoxyglucose (FDG) and prostate-specific membrane antigen (PSMA) PET/CT findings in Korean men with advanced metastatic castration-resistant prostate cancer (mCRPC)., Materials and Methods: The results of paired FDG and PSMA PET/CT examinations performed in 42 consecutive men with prostate cancer for treatment planning after failure of anti-androgen therapy and chemotherapy were studied. Tumor lesions with FDG or PSMA uptake intensity higher than that of the liver on visual review were considered positive and noted per patient and tumor site (prostate bed, lymph node, bone, and visceral organ). The presence of unequivocally discordant FDG and PSMA uptake patterns in tumor lesions was assessed. Patients were grouped according to the total tumor volume as seen on each PET/CT scan, and the clinical findings between the patient groups were compared using the Mann-Whitney U test., Results: On patient-based analysis, the image findings were PSMA+/FDG- in 2 patients, PSMA-/FDG+ in one, and PSMA+/FDG+ in 39 patients. On site-based analysis, the discordance (PSMA+/FDG- or PSMA-/FDG+) rate was 9.5% (4/42) for prostate/bed, 11.9% (5/42) for lymph nodes, 9.5% (4/42) for bones, and 11.9% (5/42) for visceral organs. FDG uptake was higher than PSMA uptake in at least one tumor site in 54.8% (23/42) of patients. Patients with greater total tumor volume on FDG PET/CT than that on PSMA PET/CT ("FDG-dominant pattern") accounted for 28.6% (12/42), and they had significantly shorter time from diagnosis (median 25 months vs. 62 months, P = 0.049), and higher aspartate aminotransferase (median 28.5 vs. 22.5, P = 0.027) and lactate dehydrogenase (median 341.5 vs. 224.5, P = 0.010) levels., Conclusion: Most patients with advanced mCRPC had tumors with positive findings on both FDG and PSMA PET/CT. However, the uptake patterns varied; 54.8% of the patients had tumor(s) with FDG uptake greater than PSMA uptake, and FDG-dominant pattern was noted in 28.6% of the patients., Competing Interests: Joo Hyun O, who holds respective positions on the Editorial Board Member of the Korean Journal of Radiology, was not involved in the editorial evaluation or decision to publish this article. Seunggyun Ha has consultant agreement with FutureChem. Joo Hyun O has consultant agreements with FutureChem and Novartis. The remaining authors have declared no conflicts of interest., (Copyright © 2024 The Korean Society of Radiology.)- Published
- 2024
- Full Text
- View/download PDF